MedTrace Logo

Evaluate the Safety and Pharmacokinetics of Ricolinostat

NCT05193851 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-04-03

No results posted yet for this study

Summary

This study is an open-label, phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.

Conditions

  • Peripheral Nervous System Diseases

Interventions

DRUG

ricolinostat

This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects. 12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug. This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period.

Sponsors & Collaborators

  • Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaojiao Li · China

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-12
Primary Completion
2022-01-30
Completion
2023-01-06
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05193851 on ClinicalTrials.gov